Compare ResMed Inc. (RMD) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? ResMed Inc. trades at $222.39 (market cap $31.92B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.97. The key difference: ResMed Inc. pays a 1.2% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and ResMed Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| RMD | TMF | |
|---|---|---|
Market Cap | $31.92B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.73 | $44.14 |
52-Week Low | $182.82 | $30.59 |
Enterprise Value | $31.28B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $31.43 with a modest 0.67% daily gain. Technical indicators show a bearish bias overall, with moving averages signaling caution, though oscillators are neutral. The ETF, which provides 3x leveraged exposure to long-duration U.S. Treasuries, faces significant volatility due to its daily leverage reset mechanism. Recent news highlights its high-risk nature, with one article noting a substantial decline from a $10,000 investment five years ago to approximately $1,527, underscoring the perils of long-term holding.
The outlook for TMF is highly speculative and tied to interest rate movements. While some see opportunity at perceived lows in the bond market, the consensus warns it is unsuitable for long-term investment. Primary risks include extreme volatility from daily leverage resets and adverse shifts in Treasury yields. It remains a tactical, short-term instrument for experienced traders, not a core portfolio holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
